Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2020-Results-Delivered-GAAP-Net-Income-of-25-Million-and-Adjusted-EBITDA-of-33-Million/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2020-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2020-Investor-Update-Call/default.aspx
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Announces-Updates-Designed-to-Strengthen-IW-3718-Phase-III-Program-for-Refractory-Gastroesophageal-Reflux-Disease-GERD/default.aspx
Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Announces-Updates-Designed-to-Strengthen-IW-3718-Phase-III-Program-for-Refractory-Gastroesophageal-Reflux-Disease-GERD/default.aspx
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-AbbVie-Report-Top-line-Phase-II-Data-for-MD-7246-in-Patients-with-Abdominal-Pain-Associated-with-Irritable-Bowel-Syndrome-with-Diarrhea-IBS-D/default.aspx
Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-AbbVie-Report-Top-line-Phase-II-Data-for-MD-7246-in-Patients-with-Abdominal-Pain-Associated-with-Irritable-Bowel-Syndrome-with-Diarrhea-IBS-D/default.aspx
Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-First-Quarter-2020-Results-and-Provides-Update-on-Impact-of-COVID-19-Pandemic/default.aspx
Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-First-Quarter-2020-Results-and-Provides-Update-on-Impact-of-COVID-19-Pandemic/default.aspx
Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-Allergan-Receive-Notices-of-Allowance-for-Patent-Applications-Covering-72-mcg-Dose-of-LINZESS-linaclotide/default.aspx